

Supplementary Materials

Table S1. Detailed keywords used in databases.

Database	Keyword combination
PubMed	<ol style="list-style-type: none"> 1. (long-acting OR “long acting” OR weekly OR once-weekly) AND (growth hormone OR gh OR hgh OR rhgh OR somatropin OR somatotropin) 2. LAGH 3. Sogroya 4. somapacitan 5. #1 OR #2 OR #3 OR #4 6. Growth Hormone Deficiency OR GH Deficiency 7. #5 AND #6
EMBASE	<ol style="list-style-type: none"> 1. (long-acting OR “long acting” OR weekly OR once-weekly) AND (growth hormone OR gh OR hgh OR rhgh OR somatropin OR somatotropin) 2. LAGH OR Sogroya OR somapacitan 3. #1 OR #2 4. Growth Hormone Deficiency OR GH Deficiency 5. #3 AND #4
Scopus	<ol style="list-style-type: none"> 1. Sogroya 2. somapacitan 3. LAGH 4. ((long-acting OR “long acting” OR weekly OR once-weekly) AND (growth hormone OR gh OR hgh OR rhgh OR somatropin OR somatotropin)) 5. #1 OR #2 OR #3 OR #4 6. Growth Hormone Deficiency OR GH Deficiency 7. #5 AND #6




Figure S1. Forest plot of subgroup odds ratio of adverse events symptoms.




Figure S2. Adverse events related to trial products.




Figure S3. Serious adverse events.




Figure S4. Forest plot of proportions of adherence of Somapacitan.




Figure S5. Forest plot of proportions of adherence of Norditropin.